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- IV -Report of the Scientific Comnittee for Food on Antioxidants 
(Opinion expressed 11 December 1987) 
TERMS OF REFERENCE 
To review the avai table data on the safety of antioxidants. 
BACKGROUND 
The Committee has carried out ad hoc reviews of the safety of a mmber of antioxidants over 
a period of time: 
- gallates, 2 July 1976; 
- tertiary butylhydroquinone (TBHQ) (unpublished); 
- butylated hydroxyanisole (BHA), 29 April 1983; 
- erythorbic acid (unpublished). 
Following these evaluations, and particularly that of BHA, the Committee recommended that 
the safety of other antioxidants should also be assessed. This review became more pressing 
with the disclosure in 1983 of suspected adverse effects of butylated hydroxytoluene (BHT) 
in rats, and the Commission decided that the Committee should undertake a complete revision 
of a number of substances listed as antioxidants in the Directive on Antioxidants. 
This view was undertaken up to March 1986 and the results made known to interested parties. 
In the meantime new data have become available, and prior to publication of the report the 
Committee (reconstituted in April 1986) has been asked to advise on whether these new data 
would affect the conclusions drawn in 1986. 
The Committee believes that it would be premature to undertake a further major review at 
this time as clarification of a nunber of outstanding questions, particularly on BHA, is 
expected to become available during the next two to three years. At that time, or sooner, 
if the data are such as to warrant more immediate change, the Committee would wish to 
undertake a further comprehensive review of the safety of antioxidants. In the meantime 
the earlier conclusions remain valid. The substances included in the review are 
L-ascorbic acid (E 300); 
Sodium L-ascorbate (E 301); 
Calcium L-ascorbate (E 302); 
Ascorbyl pa Imitate (E 304); 
Tocopherol extracts (E 306); 
Alpha-tocopherol (E 307); 
Gamma-tocopherol (E 308); 
Delta-tocopherol (E 309); 
Propyl gal late (E 310); 
Octyl gallate (E 311); 
Dodecyl gal late (E 312); 
Butylated hydroxyanisole (E 320) 
and Butylated hydroxytoluene (E 321). 
Data were also provided on the antioxidants 
Tertiary butylhydroquinone (TBHQ) 
and Erythorbic acid. 
The Committee was assisted in its review by documentation provided by the Confederation of 
the Food and Drinks Industries of the EEC on the mode of action of antioxidants, the need 
for their use and possible hazards in the absence of antioxidants. Information on current 
national legislation reflecting current usage patterns was provided from the Commission 
files. 
Committee members participated in an ad hoc working group of experts on antioxidants which 
took place 25, 26 October 1984. 
Many toxicological data available only in summary form to the ad hoc working group were 
presented to the Committee during the present review. The main sources of toxicological 
data are referenced. 
MECHANISMS OF OXIDATION 
Unsaturated fatty acids are peroxidised in the presence of molecular oxygen by a three-step 
reaction involving free radical initiation, propagation and finally the appearance of 
secondary products (terminal process). 
In the initiation step, the unsaturated lipid (LH) is converted via hydrogen abstraction 
into a lipid free radical L. in a process catalysed by light, heat or traces of transition 
metals. This carbon-centered radical is oxidised by molecular oxygen to a lipid peroxyl 
radical LOO. which is capable of participating in the initiation process by abstracting hydrogen frcm another Lipid molecule (LH) thus leading to propagation of the oxidation 
reaction. The lipid hydroperoxide formed by hydrogen donation to the peroxyl radical 
decomposes by secondary reactions to a wide variety of monomeric and polymeric products the 
chemistry of which is not yet fully understood. In the terminal process, low molecular 
LO. which in turn will break down on heating or metal catalysis to various types of 
secondary products including aldehydes, ketones, alcohols, esters, alkyl radicals and short 
chain hydrocarbons. 
LH —) L. + H. 
+ 0 —) LOO. 
LOO. + LH —) LOOH + L. 
LOOH —) LO. + OH. 
Chain termination processes include : 
L. + L. —) secondary products 
LOO. + L. —) secondary products 
LOO. + LOO. —) secondary products 
the third of which is probably the most important at normal oxygen pressures. 
Three essential objections to the presence of products of lipid peroxidation in food can be 
advanced : 
1. A number of volatile secondary products give rise to off-odours and off-flavours which 
are not acceptable to the consumer. 
2. The nutritional value of food may be decreased by the destruction of unsaturated fatty 
acids and of other essential food constituents possessing an unsaturated structure, 
e.g. Vitamin A. 
3. Adverse health effects have been ascribed to the ingestion of lipid peroxidation 
products though this topic has not been extensively studied. It is, however, clear 
that : (a) certain peroxidation products such as ma Lore Idehyde and hydroperoxy derivatives of 
methyl linoleate and methyl linolenate are mutagens and that 
(b) lipid peroxidation induced in vivo is associated with detrimental disturbances of 
membrane integrity and function. Rancidity itself may limit the intake of lipid 
peroxides. 
ACTION OF ANTIOXIDANTS IN FATS AND OILS 
Phenolic antioxidants (AH) interfere with lipid peroxidation by reaction with the radicals 
formed : 
LOO. + AH ~) LOCH + A. 
LO. + AH —) LCH + A. 
L. + AH —) LH + A. 
OH. + AH —) r^O + A. 
Among these reactions, scavenging of the carbon-centered radical L. is assumed to be less 
efficient than scavenging of the oxygen-centered radicals, especially of the penoxyl 
radical LOO.. By removal of LOO. the antioxidant has a chain-breaking action; this action 
is most powerful during the early induction period when peroxide accumulation proceeds 
slowly but will be less successful once considerable peroxide levels have been achieved. 
At elevated temperatures when peroxide formation is accelerated optimal antioxidant 
concentrations are higher than those at room temperature. 
Antioxidants are themselves converted into radical species during their inhibitory action 
on lipid peroxidation. These phenoxyl radicals A. undergo a variety of reactions : 
1. The radical can be further oxidised to yield a stable qui none. 
2. The parent antioxidant can be regenerated by reducing agents; this is a fundamental 
mechanism of synergism between individual antioxidants (see below). 
3. Dimerisation can take place, and oligomers can also be formed. 
4. The radical can form adducts with lipid peroxyl radicals to yield various non-radical 
species. 
4 -The fate of antioxidant-derived phenoxyl radicals has been studied in model systems using 
well-defined substrates such as a specific linoleic acid hydroperoxide or 
tert-butylhydroperoxide, and the structure of oligomers and adducts has been described. 
However, little is known about the fate of antioxidants in peroxidised fats and oils. 
At very high antioxidant concentrations, the removal of the antioxidant-derived phenoxyl 
radicals by the processes listed above may be incomplete, and pro-oxidative effects of the 
remaining radicals may occur. 
Optimun antioxidative concentrations at a given temperature do exist for phenolic 
antioxidants, notably tocopherols, which when exceeded result in decreased instead of 
increased stability of the fat or oil to be protected. 
SYNERGISM 
Synergism can take place between two antioxidants or between en antioxidant and another 
type of compound. Two fundamental mechanisms of synergism can be described : 
The synergist acts by regenerating the parent antioxidant molecule AH from the phenoxyl 
radical A. which has been formed by the protection process. The synergism between 
ascorbic acid, ascorbate or ascorbyl palminate on the one hand and tocopherols on the 
other hand is commonly ascribed to such action. The action of Vitamin C coumpounds on 
peroxidising lipid may however not be restricted to such synergist effects; a scavenger 
effect on peroxyl and alkoxyl radicals has not been excluded. The synergism between 
BHA and BHT has been studied in a model system using the peroxyl radical prepared from 
tert-butylhydroperoxide, and it was shown that the BHA phenoxyl radical accepts 
hydrogen from BHT to regenerate BHA while BHT itself is oxidised to the quinone 
methide. 
Functional synergism is present between phenolic antioxidants and metal sequestering 
agents like citric acid, phosphoric acid or EDTA; the latter will decrease the 
concentration of free transition metal ions and thus remove highly active catalysts of 
the initiation process and of the hydro-peroxide decomposition process. 
The present Council Directive on antioxidants in food contains a list of substances which 
enhance the antioxidant effect of primary antioxidants. The safety in use of these 
substances which may also fulfil other technological functions in food is presently being 
reviewed by the Committee. 
Citric acid and phosphoric acid are particularly useful in vegetable oils, but not animal 
fats. This has been ascribed to the fact that, while vegetable fats contain significant 
quantities of tocopherols, animal fats usually contain very little. Hence the acids 
involved in this synergism cannot fulfil their function. NEED FDR ANTIOXIDANTS 
Antioxidant technology is important in preserving edible fats, oils and lipid-containing 
food from development of objectionable flavours and odours, such as those resulting from 
oxidative rancidity and from formation of decomposition products which, as mentioned 
earlier, may be harmful. Furthermore, the nutritional quality of foodstuffs may be 
decreased by the oxidative loss of the fat soluble Vitamins A and E, or of unsaturated 
fatty acids. Antioxidants, to beeffective, must be used with food materials of good 
quality. They will not protect (or mask) fat or fatty food which has already deteriorated 
frcm abusive storage or which was prepared from unsound raw materials. Best results can 
be expected only if the antioxidants are incorporated promptly into freshly-prepared 
products of good quality and if these products are subsequently packaged properly and 
stored under correct conditions. 
The Committee was informed that antioxidants are used for a number of purposes. They can 
be of use in maintaining organoleptic quality by avoiding rancidity. There is economic 
benefit in the extension of the shelf-life of the foodstuff (this may be of significance 
for foodstuffs processed in one country and sold in other EEC countries or for foodstuffs 
of low consumption, for which a long shelf-life is desirable). As regards the 
technological benefits, very often the final processor of the foodstuff has to store an oil 
or fat used as an ingredient. These ingredients need protection during storage and before 
further processing can take place and the antioxidant has technological usefulness in 
maintaining the ingredient in good quality. 
Information submitted to the Committee suggests the principal, but not exclusive, uses of 
antioxidants are to be found in the following groups of foodstuffs. 
Vitamin preparations - preservation of vitamin content 
Flavours ) - sensitive compounds, e.g. terpenes, aldehydes oxidize essential 
oils ) easily 
Animal fats ) 
Gutter fat ) 
Veoetable oils ) 
Shortenings ) - protection of the oil or fat component of the product 
Biscuits ) 
Crisps ) 
Snack foods ) 
Nuts ) Chewing gum ) - preservation of the unsaturated nature of the gum base; antioxidant remains 
in the base and is not normally ingested in significant quantities 
Dried soups ) - protection of unsaturated fatty acids which give the characteristic flavour 
Mayonnaise and ) - protection of oil content during storage 
emulsified sauces ) 
Salted margarines ) - animal fat based margarines require additional antioxidant 
Fbtato granules, ) - protection of unsaturated fatty acids; protection of the 
flakes end powder) product during processing and storage 
LEVEL OF USE; DftlLY INTAKE 
The Committee was provided with information on usage levels of antioxidants in food in the EEC 
Member States. This information showed considerable differences in usage patterns. It 
appears that these differences have been caused by a combination of several factors (e.g. 
special rules on the types of oil which might be used for specific purposes, availability 
of particular antioxidants, recipe traditions, distribution network). For similar 
reasons, only limited information was available to the Committee on interchangeability of 
antioxidants and the consequences that could ensue if the use of one or other substance 
were to be curtailed. 
Nevertheless, the Committee was given estimates of possible total intake of antioxidants 
which varied from about 14 mg/person/day based on theoretical calculations to about 1 mg 
based on statistics on production and sale of antioxidants in the EEC. 
Neither approach takes into account the losses of antioxidants during processing. This 
varies according to the foodstuff in question and the antioxidant concerned. In the case 
of phenolic antioxidants used in biscuits and snack foods (their main use), the figures for 
loss are said to be of the order of 35% and 50-90% respectively. 
The daily intake (maximum) of BHA has been estimated to be 4 mg in the Netherlands. BHT 
and gallates were not detected in the foods examined. 
The Committee emphasised the need for more extensive information on the daily intake of 
antioxidants, including knowledge of the intake of individual compounds. NUTRITIONAL IHPLICATIONS RELATING TO POLYUNSATURATED FATS AND OILS 
This review is not concerned with the problems of diet or with consideration of the 
possible advantages or disadvantages of polyunsaturated fats in comparison with other fats. 
However, it should be noted that in the absence of antioxidants, the dietary level of 
polyunsaturated fats may fall. 
TOXIC0L0GICAL EVALUATION 
A summary of the evaluations is given in Annex 1. 
The Committee's assessments of individual substances are contained in Annex 2. However, 
some general comments are pertinent. 
Many reviews have appeared on the biological effects of lipid oxidation products and their 
relevance to cancer. Lipid oxidation products have been implicated in the disruption of 
biological membranes, the inactivation of enzymes and damage to proteins, the formation of 
age pigments in damaged cell membranes, oxidative damage to the lung by atmospheric 
pollutants, and in the causation of cancer. It is postulated that chemical carcinogenesis 
results from oxidation of chemical agents into reactive intermediates; and experimental 
studies in which antioxidants, such as BHA and BUT, have been shown to possess 
anti-carcinogenic properties have been interpreted as demonstrating beneficial effects of 
anti-oxidant activity in scavenging free radicals. However, this is probably of little 
relevance to the use of antioxidants as food additives where the intakes are small compared 
with those employed experimentally - and there is no evidence that such direct benefits to 
health (as might arise from prevention of in vivo auto-oxidation) results from the 
ingestion of food to which antioxidants have been added for important technological 
purposes, tor is it clear the extent to which ingestion of foods which in the absence of 
added antioxidants could contain lipid oxidation products would alter the actual intake of 
such products or be likely to lead to adverse health effects. Rancidity itself may limit 
intake. 
In assessing the safety 'in use' of individual antioxidants the Committee raised questions 
of wider toxicoloeical principle. The results of recent carcinogenicity studies with BHA 
and RMT (together with data from subsequent research into specificity and mechanism of 
action of RH/O mad? it necessary to consider both the concept of a threshold for 
tumorinenesis (in the absence of evidence of genotoxicity) and whether effects in the 
rodent forestomach should be considered significant for prediction of effects on human 
health. 
The Committee considered that if such tumour production is either irrelevant in the context 
of risk to the consumer, or capable of being dealt with in the same way as any other toxic 
effect with a demonstrable threshold, then the usual safety factor should be employed in 
using a NEL to establish an ADI. Furthermore, if the tumorigenic properties of BHA and 
BHT in rodents are not considered important as predictors of possible effects in humans 
then there should be no need to carry out strictly conpareble types of tong-tem/carcinooenicity studies with other phenolic antioxidants. Likewise, if the 
effects of RHA on the rodent forestomach are not considered relevant for man, then 
distinction between other antioxidants on the basis of their ability to produce hyperplasia 
in this organ should not be part of the assessment of their safety in use. 
The Committee recognised that there was a threshold for the norrgenotoxic tumorigenic 
effects of BHA and BHT. In the case of BUT, it was decided that since the NEL for 
tumorigenesis is higher than that for haemorrhagic and other toxic effects, the ADI should 
be based on these latter effects, with a standard safety factor of 100. It was not 
considered necessary to ask for carcinogenicity studies of similar design to be carried out 
on other phenolic antioxidants. With BHA, although the Committee thought the effects on 
the rodent forestomach were unlikely to be relevant for man (and were reassured by results 
frcm species without a forestomach) they did not feel able to dismiss the forestomach 
findings completely - and used the MEL for induction of hyperplasia in the rat forestomach 
as the basis for setting an ADI, without using a greater safety factor than usual. 
Whether there is a need for further studies of induction of forestomach hyperplasia by 
other antioxidants, will depend on the results of ongoing studies with BHA. 
The Committee recommended that the Commission carry out regular reviews of the toxicology 
and levels of use/intake of the food additive antioxidants. This is to ensure that the 
intakes of BHA and BHT are indeed acceptable, and that any changing patterns of use, in the 
wake of recent concerns with BHA and BHT, do not result in any undesirable increase in the 
use/intake of other antioxidants, given the possible need to use proportionately.larger 
amounts of other compounds to achieve the same technological effects. 
In the case of ascorbic acid and .tocopherols, the Committee did not think it appropriate to 
set an ADI for a vitamin present naturally in the diet at far higher levels than would be 
contributed by their use as antioxidants. 
- 9 -ANNEXES ATf£X 1 
SUTWARY OF CONCLUSIONS 
L-ascorbic acid 
Sodium L-ascorb?te 
Calcium L-ascorbate 
(E300) 
(E301) 
(E302) 
Acceptable 
Ascorbyl paImitate  (E304) 
Isoascorbic acid 
(Erythorbic acid) 
Tocopherol extracts 
Alpha-'tocopherol 
Gamma-tocopherol 
Delta-toconherol 
Propyl pa I late 
Octyl dilate 
Dodecyl pal late 
Rutylated hydroxyanisole 
Rutylated hydroxytoluene 
Tertiary butylhydronuinone 
(E306) 
(E307) 
(E308) 
(E309) 
(E310) 
(E311) 
(E312) 
(E320) 
(E321) 
Mot acceptable 
Acceptable 
Group ADI 
Temporary ADI 
ADI 
Not acceptable 
0-0.5 mg/kg bw 
0-0.05 mg/kg bw 
13 -AWEX 2 
ASSESSMENT OF INDIVIDUAL ANTIOXIDANTS 
L-ascorbic acid, and its calcium and sodium salts 
Ascorbic acid (Vitamin C) is present in many rapidly growing leafy vegetables, tomatoes, 
potatoes and fruits. Foods of animal origin are poor sources. Only L(+) ascorbic acid is 
used as a food additive. 
Ascorbates are used as inhibitors of enzymatic browning, as antioxidants in a variety of 
foods and beverages. 
Toxicological data from short-term, long-term, reproductive and teratogenicity studies were 
available and showed no evidence of adverse effects even at relatively high dosage (from 
1-2 g/kg bw/d). Mutagenicity data show that ascorbic acid does not cause gene mutations 
and although in vitro tests suggest that it causes DNA strand breaks and chromosome damage, 
the limited in vivo data are negative. Ascorbic acid appears to be able to potentiate or 
inhibit the mutagenic effects of other chemicals. 
Some studies in man indicated a diuretic effect at 5 mg/kg bw and glycosuria at 
30-100 mg/kg bw - but these results were not confirmed in large scale, double blind 
studies. Daily therapeutic doses of the order of 100 mg/kg bw over a long period have not 
shown adverse effects. 
It is estimated that the normal daily intake of ascorbic acid from natural sources is 
30-100 mg. The Committee considered that the use of ascorbic acid end its calcium and 
sodium salts as food additives would represent only a very small fraction of the total 
dietsrv intake. 
The Committee therefore decided it was inappropriate to establish an ADI for L-ascorbic 
acid and its calciun and sodium salts, which they found acceptable 
for food additive use. 
- 14 -Ascorbyl palmitate 
Ascorbyl palmitate is presumed to yield ascorbic acid during digestion. 
Ascorbyl palmitate is used as an antioxidant in cooking fats. The commercial material 
tested was thought to have contained 5-20% ascorbyl stearate and 80-95% palmitate. The 
data would therefore be suitable for evaluating the stearate. 
Toxicological data from short-term (up to nine months) and long-term studies were available 
in which no adverse effects were noted at 0.25% in the diet. The formation of bladder 
stones in a few animals in high dose groups was not thought to be relevant for man. 
The Committee decided that ascorbyl palmitate was acceptable, with ascorbic acid and its 
salts, for food additive use. 
Isoascorbic acid - opinion expressed in September 1984 
The Committee was asked to consider the safety in use in food of isoascorbic acid 
(erythorbic acid) as an antioxidant, particularly in meat products and in (imported) wines. 
The Committee was informer! that isoascorbic acid can be used in meat products for the same 
purposes as ascorbic acid, corresponding quantities having the same technological effect. 
The use of isoascorbic acid in wine is not authorised at Community level but discussion has 
l-pen taking place to amend these rules, ?t least as far as imports are concerned. 
The Committee has not considered in retail the special problems that might exist for all 
salts of isoascorbic acid, but its opinion on the acid itself is valid also for the sodium, 
notassium and calcium salts. 
Isoascorbic acid was evaluated by JECFA in 1961 and 1973. An ADI of 0-5 mg/kg bw was 
established by that Canmittee on the basis of a long-term study in rats. Since that time 
a considerable amount of additional studies have become available, which are concerned 
particularly with the biological behaviour of the substance. Therefore a reappraisal of 
th° totality of the data had becone necessary. 
Although the amarpnt anti-scorbutic activity of single doses of isoascorbic acid is about 
5% of thit of ascorbic acid, largo doses over prolonged periods will relieve the symptoms 
of scurvy. Isoascorbic acid is absorbed less efficiently and can compete with ascorbic 
acid for transport mechanisms. It reduces the ascorbic acid body pool and increases 
15 ascorbic acid turnover, reduces its half-life and depresses the bioavaiability of ascorbic 
acid by almost 50%. Isoascorbic acid is largely excreted in the urine but the fate in the 
body of 30-50% is unknown; nor are the metabolites known. Some human tissues appear to 
have stereospecific uptake. Unpublished data suggest failure of isoascorbic acid to be 
transported into granulocytes and inhibition of ascorbic acid uptake in man. The 
available short-term and long-term studies are inadequate as only one dose level was 
tested. Although no adverse effects were noted, there is no information on reproductive 
function or teratogenicity. The biological competition with ascorbic acid may be of 
significance for people with marginal ascorbic acid intake. The estimated intake may be 
6-8% of the daily ascorbic acid requirement. 
The Committee concluded that the available data are inadequate for full toxicological 
evaluation of the substance. Furthermore, the Committee was aware of the possibility that 
the observed competitive interference of isoascorbic acid with the absorption and 
distribution of ascorbic acid, and the resultant depletion of body reserves of ascorbic 
acid, could be of significance for people with border line intakes of ascorbic acid. The 
Committee was therefore of the opinion that the use of isoascorbic acid in food and drink 
is not acceptable, and no ADI was established. 
Tocopherol extracts; alpha-, beta-, gamra- and delta-tocopherol; alpha- tocopherol acetate 
Vitamin E consists of a group of eight closely related compounds, namely four tocopherols 
and four tocotrienols. Particularly abundant in vegetable oils are alpha-, beta-, garrora-
and delta-tocopherol. They all contain an hydroxy-bearing aromatic ring system and an 
isoorenoid side-chain, but differ in the number of methyl groups bound to the aromatic 
ring. There are three such methyl groups in alpha-tocopherol, two in beta- and 
gamma-tocopherol, and only one in' delta-tocopherol. 
Nutritional deficiency of Vitamin E in rodents leads to sterility and muscular weakness and 
atrophy. In humans evidence of tocopherol deficiency approaching the severity of that 
noted in animals has been observed in patients with long-standing fat malabsorption in 
association with clinical conditions such as neuropathy and myopathy. The specific 
molecular functions of the Vitamin E compounds is not known with certainty but there is 
good evidence that they are closely associated with lipids throughout the body and active 
in stabilizing highly unsaturated fatty acids in the cell against oxidation. A protective 
effext of tocopherols on the integrity of cell membranes is also established. In 
evaluating relative biological activities of the tocopherols including the anti-haemolytic 
and in vivo anti-oxidative activity, the number and position of the methyl groups in the 
benzene ring are important. The most active form is (d)-alpha-tocopherol. 
(d)-beta-tocooherol has about 25%-50% such activity; and (d)-gamma-tocopherol has about 
10%-37% as much as (d)-alpha-tocopherol, depending on the assay used. 
The recomnended daily dietary intake of Vitamin E, expressed as (d)-alpha-tocopherol 
equivalents, is 10 mg/adult male and 8 mg/adult female. The recommended intake of Vitamin 
E increases during pregnancy and lactation by 1 and 3 mg/day, respectively. These intakes 
are likely to be met by the levls of tocopherols naturally occurring in many foods such as 
vegetable oils, cereals, nuts and leafy vegetables. 
16 Clinical data are available indicating that adult humans can ingest for a few years daily 
doses of Vitamin E in the order of 100 mg or above without adverse effects. 
Hypervitaminosis has been reported in human beings only at oral dosage levels in excess of 
400 mg/day. An increased mortality risk has been claimed to be associated with intakes of 
Vitamin E in excess of 1 g/person/day. On the whole, these data are not sufficient to 
assess long-term effects in humeri subjects of high intakes of Vitamin E. 
In view of their antioxidant properties, tocopherols are also used as additives in food to 
prevent the destructive, non-enzymatic attack of molecular oxygen on the double bonds of 
the polyunsaturated fatty acids. The relative antioxidant efficiency of the different 
tocopherols in foods depends upon the nature of the substrate, the temperature and, 
possibly, the concentration. For example, gamma-^tocopherol was more active than delta-
tocopherol and much more than alpha-tocopherol in inhibiting oxidation of lard at 97°C, 
whereas gamma-tocopherol was the most effective, closely followed by the alpha-form, in 
protecting safflower oil at 63°C. 
The tocopherols commercially available as food additives are mixtures of natural compounds 
(E306) or single synthetic (d,l) alpha-(E307), gamma-(E308) and delta-tocopherol (E309). 
The E306 obtained from vegetable oils is a mixture of (d) alpha-, beta-, gamma- and 
ctelta-tocopherol; the proportion of these four forms varies according to the source of 
the oil. Thus, for example, (d) alpha-tocopherol is predominant in sunflower and olive 
oil, whereas (d) gamma- and delta-tocopherols predominate in soybean oil. Other mixtures, 
called "mixed tocopherols" and "80-20 nixed tocopherols", are sold mainly for their Vitamin 
E activity, they contain not more than 5% or 20% of norralpha-tocopherol respectively, the 
rest being (d)alpha-tocopherol. Under some circumstances, tocopherol esters (i.e. acetate 
and succinate) of (d) alpha- or (d,l) alpha-forms are also commercially available. 
Metabolism and toxicity data are almost entirely based on studies of alpha-tocopherol and 
its acetate. 
Ingested tocopherols are absorbed, translocated to tissues and metabolised (d) 
aloha-toconherol is retained in the issues longer than other forms of Vitamin E. 
Tocopherols (i.e. (d) alpha-tocopherol, (d,l) alpha-tocopherol and (d,l) alpha-tocopherol 
acetate) are characterised by very low acute oral toxicity. Several animal species can 
tolerate doses of 200 mg/kg bw without apparent toxic signs. 
Conditions described as hypervitarinosis E, including changes in oestrus cycle and 
degenerative lesions of liver and myocardium, have been reported in guinea pigs, hamsters 
and rats on subchronic administration,, particularly by intra-muscular dosage in the range 
of 1 n of aloha-tocooherol/kg bw or hioher. 
Chronic toxicity studies with (d,l) alpha-tocopherol acetate suggested a limit hepatic 
response to Vitamin E overload as judged by liver enzymes and weight. They also indicated 
the possibility of interactions with other vitamins, e.g. Vitamins A and K in the diet, and 
the need for preventing vitamin itbalance at high intakes of Vitamin E. However, a 
- 17 -dose-related onset of haemorrhage, controlled by Vitamin K supplementation, also occurs 
with BHT. Both antioxidants appear to act by altering the availability of Vitamin K. 
Apart from the fact that BHT is not a vitamin, the reasons for considering that its effect 
is "toxic", while that of tocopherol may reflect "vitamin imbalance" are based on 
differences in dose response and the fact that there is some evidence that tocopherol can 
also interact with Vitamin A. However, it should be pointed out that studies on the 
effect of low doses of tocopherol on the prothrombin time, in the absence of Vitamin K 
supplementation, have not been carried out. Studies in human subjects suggest that large 
doses of tocopherol only decrease the levels of Vitamin K dependent clotting factors in the 
presence of pre-existing abnormalities, e.g. warfarin therapy. At a dose level in rats of 
about 500 mg/kg bw/d and after Vitamin K supplementation, only some borderline and 
equivocal effects, such as vacuolation of hepatic macrophages, have been observed. Some 
metabolic effects (e.g. alterations in the levels of ADP, ATP, phospolipids and cholesterol 
in the liver, and in the excretion of thiamine and phosphorus) have been reported 
(abstracts only were available to the Committee) following subchronic administration of 
tocopherols and tocopherol esters to rats at dose levels close to or lower than 
500 mg/kg bw. However, as indicated by the results of the long-term studies, these 
metabolic changes do not result in toxic manifestations on prolonged treatment. 
No adequate reproductive or teratogenicity studies in mammals are available for 
tocopherols. Some investigations which only focussed on certain specific effects (e.g. 
fetal survival and resorption, and some testicular functions) have been carried cut with 
(d,l) alpha-tocopherol acetate or (d) gamma-tocopherol, in several species, including rats, 
hamsters, rabbits and mice. These studies (which were only available as abstracts) did not 
indicate any adverse effects apart from increased mortality of off-spring in rabbits and 
hamsters at high doses (1 600 and 750 mg/kg bw respectively). 
Several investigations have fed or injected rats or mice with various doses of 
(d) aloha-tocopherol, (d,l) delta-tocopherol or (d,l) alpha-tocopherol acetate and have 
reported no increased incidence of tumours. Some in vitro and in vivo experiments 
indicate that tocopherols may have a beneficial effect, interfering sometimes with the 
formation of mutagens or with the expression of carcinogenic effects. 
Although only scanty information is available on the toxicity of beta-, gamma- and 
delta-tocopherol, the Commission,, in view of the very large amount of experimental and 
clinical data available on aloha-tocopherol, and the chemical and biological similarity of 
the four tocopherols, decided to consider the four tocopherols and alpha-tocopherol acetate 
as toxicologically equivalent. The intake of tocopherols from natural sources will 
normally far exceed that frcn processed foods containino tocooherol as an antioxidant. 
The Committee concluded that the use of tocopherols as antioxidants in food was acceptable 
mri that it was not approoriate to establish an ADI. 
18 foliates - propyl-, octyl-, doriecyl-
These three antioxidants are the n-propyl-, octyl- and dodecyl-esters of 
3.4.5-trihydroxybenzoic acid. The purity of the compound is not Less than 99% for propyl 
na I late and not less than 98.5'/. for octyl- and dodecyl gallates. Gallates are used as 
antioxidants in fats and oils (alone or in combination with other antioxidants) to prevent 
rancidity and spoilage; the gallates have been shown to be more effective antioxidants than 
RHA and BHT. Other food additive uses of gallates include shortenings, baked goods, 
candy, dried-milk, chewing gum base and food packaging materials. Information on intake 
is only available for propylgallate and has been estimated to be from 0.03-0.2 mg/kg bw/d. 
In 1976 the Scientific Committee for Food (2nd Series) established a group ADI for propyl
-, 
octyl- and dodecyl gal late for 0-0.2 mg/kg bw. This ADI was the same as that allocated by 
the WH0/FA0 Joint Expert Committee on Food Additives in 1976 and confirmed in 1980. It 
was based on a MEL observed in a reproduction study in rats of 1 000 mg of octyl gallate/kg 
feed, equivalent to 50 mg/kg bw, with the use of a 250-fold safety factor. Further data 
have since become available, including liver enzyme induction, mutagenicity, 2-generation 
reproduction, carcinogenicity (mouse and rat) and promotion/inhibition studies. 
Metabolic data are scarce but it is clear that propyl gal late is absorbed well and 
hydrolysed to propyl alcohol and gallic acid. The latter is further metabolised. 
Octyl- and dodecyl gallates are however far less well absorbed and only a minor proportion 
is hydrolysed to the alcohol and gallic acid. The acute toxicity of octyl- and dodecyl 
gallate is less than that of propyl gallate, possibly explained by the difference in 
absorption/metabolism. Gallates are mainly excreted in the faeces. 
Gallates may cause skin sensitisation and subsequent exacerbation of the resulting contact 
dermatitis occurs in some such sensitized individuals after ingestion of gallates. 
Short-term toxicity studies in rats, mice, guinea pigs, dogs and pigs were available to the 
Committee. Also, at least six long-tern toxicity/carcinogenicity studies in rats and mice 
have been carried out with propyl gallate. About half of these studies were old and/or 
inadequate. Nevertheless, there was no evidence of any increase in tumour formation. 
The NEL was 1 170 mg/kg feed in one study and 5 000 mg/kg feed in at least two other 
studies. With octyl- and dodecyl gallates only one long-term toxicity study was 
available. In this old study no toxicity, nor increase in tumour incidence was noted with 
5 000 mg/kg feed. The Committee considered that 5 000 ng/kg feed, equivalent to 
250 mg/kg bw could be considered the N'EL. In short-tem studies propyl gallate did not 
cause hyperplasia in the rat forestonach. 
Propyl gallate was tested for inhibitory and potentiation effects on carcinogenesis. 
Propyl gallate showed clear inhibitory properties against the induction of tumours by DMBA 
and/or nitrosamines; and on the effect of hepatotoxic compounds. 
19 Reproduction and teratogenicity studies were carried out with propyl- and octyl gallate. 
From these studies it was concluded that gallates are not teratogenic. On the contrary, 
gallates protected rabbits against the teratogenic potential of hydroxyurea. In the 
reproduction studies, 2 500 no/kg feed produced a few minor effects but 1 000 mg/kg feed 
was without effect. 
A range of mutagenicity studies (including dominant lethal), host mediated assay, in vivo 
cytogenetic, and Ames tests, with propyl gallate were negative. (No tests have been 
carried out for gene mutation in mammalian cells.) Mo data were available for octyl- and 
dodecyl gallate. 
The Committee concluded that although a few data were available for octyl- and dodecyl 
gallates, the fact that these compounds appeared to be less toxic than propyl gallate made 
the use of a group ADI acceptable. The Committee confirmed the previously established NEL 
of 50 mg/kg bw but did not think that there was any need to continue to use a safety factor 
or 250. The usual factor of 100 was applied. 
The Committee therefore established a group ADI of 0-0.5 mg/kg bw for propyl-,octyl- and 
dodecyl gallates. 
Butylated hydroxyamsole (BHA) 
BHA is predominantly (85% or more) 3-tert-butyl-4-hydroxyanisole (3-BHA) with 15% or less 
of 2-tert-butyl-4-hydroxyanisole (2-9HA). 
The Committee had previously considered BHA in 1978 and 1983. At that time biochemical, 
short- end long-term toxicity/carcinogenicity data were available, together with results 
from mutagenicity, teratogenicity and reproduction studies. There was no multigeneration 
study. Sore observations had also been made in man. 
The SCF evaluated BHA in 1983 following consideration of results from a Japanese study in 
which BHA had produced forestomach tumours in the rat. The Committee endorsed the opinion 
of an EC working party on BHA (October 1982) and emphasized that information should be 
obtained on whether BHA could produce epithelial hyperplasia in the oesophagus and/or 
glandular stomach of species without a forestomach, or if its action was specific for the 
rodent forestomach. 
Since that time more work has been carried out to resolve the above questions and to 
determine the nechanism for the action of BHA, and whether or not BHA is genotoxic. 
The previously available long-term studies in rats were carried cut rather a long time ago 
and it is possible that the study designs may not have taken the same account of 
forestomach lesions as was the case in the more recent Japanese studies. Also the highest 
dose used previously was 0.5% BHA in the diet. In Ito's study 2% BHA in the rat diet 
- 20 produced tumours but 0.5% did not, although hyperplasia was present. In a similar study 
carried out by Tomii and Aoki a few forestomach tumours were found at 1% dietary level of 
BHA. Because of the steep dose response curve these authors questioned whether there may 
be a threshold for the tumorigenic effect of BHA. 
Many short-term studies have been carried out in several species to determine whether BHA's 
action is specifically on the forestomach epithelium, and whether there is a threshold for 
hyperplasia. Depending on the duration of the experiment, BHA has been shown to produce 
hyperplasia and/or tumours specifically in the forestomach of rats, mice and hamsters. 
The hyperplasia is reversible but the time taken for recovery depends on duration and level 
of dosage with BHA. The NEL for hyperplasia in the rat forestomach is 0.125% BHA in the 
diet. 
In animals without a forestomach - guinea pig, dog, pig, monkey - BHA produced no 
histological effects (including no hyperplasia) in the oesophagus or glandular stomach. 
In gavage studies in the monkey, the mitotic index in the 'target' squamous epithelium of 
the distal oesophagus was raised at high dose levels, but not at 250 mg/kg bw. 
The Committee concluded therefore that the action of BHA in producing forestomach 
hyperplasia and tumours in rodents may not be relevant for man. 
Other data examined by the Committee included promotion studies and results of mutagenicity 
tests. BHA has been shown to have both inhibitory and promotional effects on tumour yield 
from treatment with known carcinogens - the inhibitory effect being stronger. Nearly all 
the available mutagenicity data were negative and BHA has not been demonstrated to be a 
genotoxic compound. This reinforced the Committee's view that the effects on the rat 
forestomach were not sinnificant for assessing risks to human health. 
The Committee had prpviously noted the lack of a multigeneration study. However, in a 
numbr of (1 generation) reproduction studies with rats, mice and monkeys, at dose levels of 
50 mg/kg bw or higher no effects were observed except on the behaviour of mice. 
Teratogenicity studies were all negative. The Committee therefore agreed that a temporary 
AOI for BHA was now acceptable. 
The Committee concluded that the production of rodent forestomach tumours by BHA was not a 
manifestation of genotoxicity; and that in addition to being an effect with a threshold, 
the preceding hyperplasia may not be of relevance for nan. Further reassurance was to be 
found in the results of studies in species without a forestomach. In setting an ADI the 
Connittee took into account that : 
(a) the NEL in ? 90-day study for production of hyperplasia in the rat forestomach 
(62.5 mn/kg bw). Given the evidence of lack of effect in more relevant species, the 
Committee considered that a safety factor of 100 was adequate; 
21 -and 
(h) the NEl of 250 mo/kg bw previously determined in a long-term chronic toxicity feeding 
stucV - on the basis of which JECFA had established a temporary ADI of 0-0.5 mg/kg bw 
(using a safety factor of 500). 
The Committe established a temporary ADI of 0-0.5 mg/kg bw. 
The Committee noted that the actual (estimated) daily intake of BHA is far less than that 
allowed by the temporary ADI. The Committee wishes regularly to review the status of BHA, 
and information from ongoing studies and on actual intakes. 
Butylated Hydroxytotuene (BHT) 
The Committee has reviewed all available studies on BHT, including metabolic data from 
several species including man, mutagenicity studies, carcinogenicity studies in rats and 
mice, and special studies on the thyroid, blood and postnatal development and behaviour. 
A recent two-generation feeding study in the rat showed an increased incidence of 
hepatocellular adenomas and carcinomas at the two higher dose levels (100 and 
250 mo/kg bw). All the tumours were first noted after two years, the majority at 
termination beween 141 and 144 weeks; and the survival of control animals was markedly 
poorer than in those fed BHT. Previous feeding studies in rats have not shown such 
carcinogenic effects. The Committee's view that the recent study suggests a threshold for 
carcinogenesis (related to liver enzyme induction) was reinforced by the results obtained 
frcm mutagenicity testing, with an overall lack of evidence of genotoxic effect in in vivo 
systens. Like other antioxidants BHT can exhibit promoting or inhibiting effects on 
carcinogenesis. BHT does not cause hyperplasia in the rat forestorrach. Effects on 
mitotic rate are diverse. 
Since the NEL demonstrated for carcinogenesis was higher than that obtained for other 
toxicolooical effects, the ADI was determined from the latter. 
The information available from a 90-day feeding study in the rat indicated there was a 
dose-related increase in relative thyroid weight of 40% and 67% in the 500 and 5 000 ppm 
BHT groups resnectively; iodine uptake and the height of follicular epithelial cells were 
increased at 5 000 ppm (not measured at 500 ppm). However, blood levels of 
tri-iodothyronine and thyroxine at both dietary levels were unchanged, and the increase in 
the half-life of thyroxine seen early in the study was only transient. In the in utero 
exposure rat carcinogenicity study, a 5% reduction in offspring body weight at weaning was 
seen in those reared by dams fed 25 mg/kg bw, equivalent to approximatey 500 ppm BHT in the 
diet. Since these effects on the thyroid and on offspring body weight were found at the 
lowest levels tested in these particular studies, MEL have not been clearly established. 
In view of these data, and the nature of the effects observed, it is reasonable to assume 
the likely NEL for thyroid and offspring body weight changes will be about 5-fold lower 
than the lowest-observed-effect level, i.e. about 100 pom in the diet. 
- 22 -A series of haematological studies has shown that some, but not all species tested show 
ha error rhaging and/or a reduction in the prothrombin index after dosing with BHT. The 
mechanisms by which BHT brings about these effects appear to be several but the major 
effect is a reduction in activity of certain clotting factors, principally those which are 
Vitamin K-dependent. The most susceptible species for haemorrhagic effects appears to be 
the rat, and for this species the NEL for transient reduction (1 week's duration) of the 
prothrombin index was 85 ppm in the diet, and for persistent reduction (4 weeks' duration), 
2 500 ppm in the diet. 
Taking all these effects into account, the Committee considered that the likely NEL for BHT 
is approximately 100 ppm in the diet, equivalent to an intake of about 5 mg/kg bw/d. In 
view of the nature of the effects, a safety margin of 100-fold is appropriate to establish 
an ADI of 0-0.05 mg/kg bw based on thyroid, reproduction and haematological effects in the 
rat. 
Tertiary4xttyLhydroquinone (TBHGO 
The Committee previously expressed its opinion on TBHQ in December 1981 when it drew 
attention to the lack of adequate data on which to assess the genotoxic and carcinogenic 
potential of this antioxidant. The Committee, therefore, did not establish an ADI at that 
time. 
Since then, further in vitro and in vivo mutagenicity data have become available which do 
not exclude the possible genotoxicity of TBHQ. 
The Committee therefore restated the need for an adequate carcinogenicity study and also 
requested an in vivo mutagenicity study of germ cell effects. 
The Committee did rot establish an ADI for TBHQ, and the substance is not acceptable for 
use as an antioxidant to food. 
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